Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dharam Anand

Internal Medicine Bourbonnais, IL Medical Doctor

NPI 1134107170 CMS profile 323554

100 Provena Way Ste D, Bourbonnais, IL 60914

Open in the dashboard

General payments

$11,459

847 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dharam Anand of Bourbonnais, IL is reported in the CMS Open Payments database as having received $11,459 across 847 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,658 82
2024 General $1,464 116
2023 General $1,548 114
2022 General $2,226 170
2021 General $2,253 174
2020 General $1,543 110
2019 General $767 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dharam Anand
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Dharam Anand were reported at $1,658. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Dharam Anand Internal Medicine median Middle half National median
2019 $767 $159 $48–$570 $163
2020 $1,543 $119 $33–$402 $114
2021 $2,253 $135 $37–$521 $132
2022 $2,226 $141 $42–$496 $149
2023 $1,548 $149 $45–$519 $160
2024 $1,464 $154 $47–$537 $164
2025 $1,658 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,608 139 payments
  2. Nestle HealthCare Nutrition Inc. $1,235 130 payments
  3. Novo Nordisk Inc $1,048 81 payments
  4. Lilly USA, LLC $673 42 payments
  5. Allergan Inc. $604 61 payments
  6. AstraZeneca Pharmaceuticals LP $521 28 payments
  7. Otsuka America Pharmaceutical, Inc. $520 26 payments
  8. Teva Pharmaceuticals USA, Inc. $485 19 payments
  9. Amgen Inc. $402 29 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $363 25 payments
  11. Other $3,998 267 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,377 846 payments
  2. Education $81 1 payment
Products named General payments · program years 2019–2025
  1. ZENPEP $1,560 171 payments
  2. UBRELVY Neuroscience $916 83 payments
  3. Ozempic $845 63 payments
  4. REXULTI $520 26 payments
  5. QULIPTA $505 53 payments
  6. UBRELVY Neuroscience $388 26 payments
  7. XIFAXAN $363 25 payments
  8. LINZESS $329 34 payments
  9. RYBELSUS $316 23 payments
  10. MOUNJARO $260 13 payments
  11. Other $8,334 547 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 167 drugs

Part D claims

11,398

Median for Internal Medicine: 777

Drug cost

$909,024

Median for Internal Medicine: $73,373

Branded share of claims

20.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 103 $118,608
Mounjaro Tirzepatide Brand 59 $85,117
Austedo Xr Deutetrabenazine Brand 12 $71,990
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 83 $58,683
Eliquis Apixaban Brand 83 $52,106
Januvia Sitagliptin Phosphate Brand 64 $50,920
Trulicity Dulaglutide Brand 40 $45,135
Jardiance Empagliflozin Brand 54 $33,936
Tresiba Flextouch U-100 Insulin Degludec Brand 23 $31,272
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 37 $30,819

The 10 drugs with the highest cost, of 167 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$131,203

Of which drugs: $393

Medicare patients

343

Average age 69

Services billed

2,741

184 women, 159 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 43%
Ischemic heart disease 34%
Diabetes 31%
Chronic kidney disease 22%
Heart failure 21%
COPD 20%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 113 418 $359
Injection, methylprednisolone acetate, 1 mg J1010 Office 13 20 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZENPEP
$312 — —
REXULTI
$185 — —
UBRELVY
$111 — —
QULIPTA
$105 — —
MOUNJARO
$85 59 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

847 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record